Status:

ENROLLING_BY_INVITATION

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

Lead Sponsor:

Sarepta Therapeutics, Inc.

Conditions:

Duchenne Muscular Dystrophy

Eligibility:

MALE

Brief Summary

This is a phase 4, multicenter, prospective, observational study designed to collect both medical history data and prospective data on Duchenne Muscular Dystrophy (DMD) treatment outcomes in participa...

Eligibility Criteria

Inclusion

  • Key
  • Is willing to provide informed assent or consent (if applicable) and has a parent(s) or legal guardian(s) or is a participant ≥18 years of age who is (are) willing to provide informed consent for the participant to participate in the study and comply with study data collection procedures.
  • Has an established clinical diagnosis of DMD, as documented prior to screening by a genetic report.
  • Receiving, or initiating treatment with, eteplirsen, golodirsen, or casimersen at the time of observational study enrollment. Note: Participants with a prescription for eteplirsen, golodirsen, or casimersen at enrollment must initiate the exon-skipping therapy within 6 months of the date of enrollment or will no longer be eligible for this study. Note: Enrollment of eteplirsen participants has been completed, no additional participants will be enrolled.
  • Key

Exclusion

  • Is currently participating in any DMD interventional study at the time of this study enrollment.
  • Has declined to provide consent for collection of their genetic data.
  • Has a medical condition or confounding circumstances that, in the opinion of the Investigator, might compromise:
  • The participant's ability to comply with the protocol-required procedures
  • The participant's wellbeing or safety, and/or
  • The clinical interpretability of the data collected from the participant.
  • Other inclusion/exclusion criteria may apply.

Key Trial Info

Start Date :

January 7 2019

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2033

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT06606340

Start Date

January 7 2019

End Date

December 31 2033

Last Update

September 10 2025

Active Locations (20)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (20 locations)

1

Arkansas Children's Hospital Research Institute

Little Rock, Arkansas, United States, 72202

2

Children's Hospital Los Angeles

Los Angeles, California, United States, 90027

3

University of California Davis Medical Center

Sacramento, California, United States, 95817

4

Children's National Hospital

Washington D.C., District of Columbia, United States, 20010

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice | DecenTrialz